Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: Virological efficacy and impact on kidney function and model for end-stage liver disease score

Journal of Viral Hepatitis

Volumn 21, Issue 9, 2014, Pages

  Virlogeux, V ^a,b,c,d   Pradat, P ^a,b,c   Bailly, F ^a,b,c   Funingana, G ^a   Goncalves F ^a   Maynard, M ^a   Hartig Lavie, K ^a   Amiri, M ^a   Zoulim, F ^a,b,c,e  

^a CROIX ROUSSE HOSPITAL   (France)

^b UNIVERSITÉ DE LYON   (France)

^c CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^d UNIVERSITÉ DE LYON   (France)

^e INSTITUT UNIVERSITAIRE DE FRANCE   (France)

Author keywords

glomerular filtration rate; hepatitis C virus; pegylated interferon; protease inhibitor; renal function; ribavirin; triple therapy; virological response

Indexed keywords

BILIRUBIN; BOCEPREVIR; CREATININE; ERYTHROPOIETIN; HEMOGLOBIN; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE; RIBAVIRIN;

ADULT; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL STUDY; COMPASSIONATE USE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFICACY; DRUG TOLERANCE; DYSGEUSIA; ERYTHEMA; FEMALE; FOLLOW UP; GENOTYPE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; NEUTROPENIA; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; PRURITUS; RASH; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; AGED; ANALOGS AND DERIVATIVES; DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; END STAGE LIVER DISEASE; GENETICS; HEPATITIS C, CHRONIC; KIDNEY; KIDNEY FUNCTION TEST; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; END STAGE LIVER DISEASE; FEMALE; GENOTYPE; GLOMERULAR FILTRATION RATE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROLINE; PROSPECTIVE STUDIES; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84905503101     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12237     Document Type: Article

References (33)

1. Lavanchy D,. The global burden of hepatitis C. Liver Int 2009; 29 (Suppl 1): 74-81.
2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ,. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144 (10): 705-714.
3. Trepo C, Pradat P,. Hepatitis C virus infection in Western Europe. J Hepatol 1999; 31 (Suppl 1): 80-83.
4. Fried MW, Shiffman ML, Reddy KR, et al,. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347 (13): 975-982.
5. Manns MP, McHutchison JG, Gordon SC, et al,. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358 (9286): 958-965.
6. Zeuzem S, Hultcrantz R, Bourliere M, et al,. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40 (6): 993-999.
7. Aghemo A, Rumi MG, Monico S, et al,. The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. Antivir Ther 2009; 14 (4): 577-584.
8. Pijak MR, Gazdik F, Hrusovsky S,. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 40 (3): 760-761; author reply 1.
9. Farnik H, Zeuzem S,. New antiviral therapies in the management of HCV infection. Antivir Ther 2012; 17 (5): 771-783.
10. Pearlman BL,. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect Dis 2012; 12 (9): 717-728.
11. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 (13): 1195-1206.
12. Bacon BR, Gordon SC, Lawitz E, et al,. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 (13): 1207-1217.
13. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364 (25): 2405-2416.
14. Sherman KE, Flamm SL, Afdhal NH, et al,. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365 (11): 1014-1024.
15. Jacobson IM, Pawlotsky JM, Afdhal NH, et al,. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat 2012; 19 (Suppl 2): 1-26.
16. Karino Y, Ozeki I, Hige S, et al,. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C. J Viral Hepat 2013. doi: 10.1111/jvh.12162
17. Poynard T, Bedossa P, Opolon P,. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349 (9055): 825-832.
18. Castera L, Vergniol J, Foucher J, et al,. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128 (2): 343-350.
19. Kamath PS, Kim WR,. The model for end-stage liver disease (MELD). Hepatology 2007; 45 (3): 797-805.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130 (6): 461-470.
21. Hollis S, Campbell F,. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999; 319 (7211): 670-674.
22. Iacobellis A, Ippolito A, Andriulli A,. Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition. World J Gastroenterol 2008; 14 (42): 6467-6472.
23. Hezode C, Fontaine H, Dufour C, et al,. Efficacy and safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotics according to the age. Data from the CUPIC cohort (ANRS CO20). Hepatology 2013; 58 (Suppl 1): 1093A.
24. Wedemeyer H, Jensen DM, Godofsky E, Mani N, Pawlotsky JM, Miller V,. Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. Hepatology 2012; 56 (6): 2398-2403.
25. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461 (7262): 399-401.
26. Suppiah V, Moldovan M, Ahlenstiel G, et al,. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
27. Tanaka Y, Nishida N, Sugiyama M, et al,. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
28. Mauss S, Hueppe D, Alshuth U,. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology 2014; 59 (1): 46-48.
29. Kunze A, Huwyler J, Camenisch G, Gutmann H,. Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Biochem Pharmacol 2012; 84 (8): 1096-1102.
30. Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB,. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol 2010; 298 (4): F997-F1005.
31. Karino Y, Hige S, Nakajima T, et al,. Telaprevir induced renal dysfunction leads to an early elevation of serum ribavirin concentration in triple therapy. Hepatology 2012; 56 (Suppl. 1): 1005A-1006A.
32. Borroni G, Cazzaniga M, Andreoletti M, et al,. Low glomerular filtration rate is a risk factor for ribavirin-associated anaemia in old patients with chronic hepatitis C. J Viral Hepat 2013; 20 (4): e90-e95.
33. Russmann S, Grattagliano I, Portincasa P, Palmieri VO, Palasciano G,. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem 2006; 13 (27): 3351-3357.